15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Acumen Pharmaceuticals Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $8.00, so the covering firms are broadly aligned. The average target of $8.00 sits 251% above the current $2.28. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.42 next quarter toward $-1.51 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Acumen Pharmaceuticals Inc.
As of Jul, 2 of 2 firms rate ABOS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABOS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.51 – $-0.33 · 3 analysts · -4% YoY
Next period, 3 analysts expect Acumen Pharmaceuticals Inc to earn $-0.42 a share (range $-0.51 – $-0.33), versus $-0.44 a year earlier. Full-year consensus is $-1.58, growing to $-1.51 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Acumen Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABOS.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$11.00+382.5% to target
Overall win rate
46%
+ Follow
#2
Thomas Shrader
BTIG
Buy
$8.00+250.9% to target
Coverage
—
+ Follow
#3
Geoff Meacham
B of A Securities
Buy
$8.00+250.9% to target
Coverage
—
+ Follow
#4
CB
Colin Bristow
UBS
Buy
$4.00+75.4% to target
Coverage
—
+ Follow
#5
Paul Matteis
Stifel
Buy
$10.00+338.6% to target
Coverage
—
+ Follow
ABOS stock forecast FAQ
What is ABOS's average 12-month price target?+
The 2 analysts with a live target average $8.00 for Acumen Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $8.00 low.
Is ABOS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ABOS?+
2 analysts have an active rating on Acumen Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABOS?+
Among analysts who currently cover ABOS, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $11.00 target.
What is Acumen Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.51 – $-0.33) across 3 analysts. Full-year EPS is projected at $-1.58, rising to $-1.51 the following year.
How much revenue is Acumen Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ABOS lately?+
As of Jul, 2 of 2 firms rate ABOS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABOS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
